PTEN and melanoma: Two representative examples of additive/antagonistic pharmacologic interactions between Trametinib and Everolimus in PTEN-competent (M14 and ME8959) and of synergistic growth inhibitory response in PTEN-loss (WM115 and C32) melanoma models are reported in Figure S5.